United Services Automobile Association’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-82,862
Closed -$1.07M 1821
2019
Q2
$1.07M Buy
82,862
+725
+0.9% +$9.14K ﹤0.01% 1289
2019
Q1
$1.29M Buy
82,137
+9,000
+12% +$156K ﹤0.01% 1217
2018
Q4
$1.47M Sell
73,137
-5,150
-7% -$113K ﹤0.01% 1126
2018
Q3
$1.95M Sell
78,287
-1,130
-1% -$30.7K ﹤0.01% 1139
2018
Q2
$2.18M Sell
79,417
-542
-0.7% -$16.3K 0.01% 1114
2018
Q1
$2.46M Buy
79,959
+1,399
+2% +$45K 0.01% 1066
2017
Q4
$2.81M Buy
78,560
+19,594
+33% +$563K 0.01% 988
2017
Q3
$1.63M Buy
58,966
+1,450
+3% +$35.1K ﹤0.01% 1114
2017
Q2
$1.52M Buy
57,516
+2,545
+5% +$56.7K ﹤0.01% 1104
2017
Q1
$1.14M Sell
54,971
-2,200
-4% -$45.2K ﹤0.01% 1077
2016
Q4
$1.18M Buy
57,171
+1,430
+3% +$23.9K ﹤0.01% 1081
2016
Q3
$904K Buy
55,741
+21,980
+65% +$319K ﹤0.01% 1125
2016
Q2
$459K Buy
33,761
+13,230
+64% +$234K ﹤0.01% 1189
2016
Q1
$358K Buy
20,531
+10,050
+96% +$205K ﹤0.01% 1222
2015
Q4
$358K Buy
+10,481
New +$363K ﹤0.01% 1273

Other funds holding RVNC

United Services Automobile Association's RVNC Position: Q3 2019 in Review

United Services Automobile Association sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2019, closing a stake of 82,862 shares — an estimated $1.07M sold.

United Services Automobile Association first reported a position in RVNC in Q4 2015 and held it in 15 quarters. The position peaked at $2.81M in Q4 2017. 109 funds tracked by Wall St. Rank hold RVNC as of Q3 2019.

  • United Services Automobile Association reported no remaining Revance Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • United Services Automobile Association sold 82,862 Revance Therapeutics, Inc. shares in Q3 2019, an estimated $1.07M.
  • United Services Automobile Association first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 15 quarters.
  • United Services Automobile Association's Revance Therapeutics, Inc. position peaked at $2.81M in Q4 2017.
  • 109 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2019.

Based on United Services Automobile Association's 13F filing for Q3 2019, filed 13 Nov 2019.